Detection of complement proteins
AssigneeComplement Therapeutics Limited
InventorsPaul BISHOP, Simon CLARK, Richard UNWIN
Life of this patent
Estimating the term…
Abstract
Methods for detecting and determining the level of complement proteins are disclosed, in particular using mass spectrometry. Also disclosed are methods of identifying subjects having or at risk of developing a complement-related disorder, and methods of treating the same.
Claims28
A method for determining the level of at least one complement protein in a sample, the method comprising:
- digesting the protein(s) with endoproteinase GluC to obtain one or more peptides;
- and
- determining the level of the one or more peptides by mass spectrometry.
-3. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-18. (canceled)
A method of treating a complement-related disorder in a subject, the method comprising:
- (a) digesting at least one complement protein in a sample obtained from the subject with endoproteinase GluC to obtain one or more peptides;
- (b) determining the presence and/or level of the one or more peptides by mass spectrometry;
- (c) using the results of (b) to determine whether the subject has an increase in the level of one or more of C3, C3b, C3a, iC3b, FHR1, FHR2, FHR3, FHR4, and/or FHR5;
- and/or a decrease in the level of one or more of iC3b, C3f, C3c, C3dg, C3d, C3g, FI, FH, FHL-1, FHR1, FHR2, FHR3, FHR4, and/or FHR5, as compared to reference value(s) obtained previously from the same subject or obtained from a subject without a complement-related disorder;
- and
- (d) treating the subject with a therapeutically effective amount of a complement-targeted therapeutic.
-21. (canceled)
A method of treating a complement-related disorder in a subject, the method comprising:
- (a) digesting at least one complement protein in a sample obtained from the subject with endoproteinase GluC to obtain one or more peptides;
- (b) determining the presence and level of the one or more peptides by mass spectrometry, wherein the subject has an increase in the level of one or more of C3, C3b, C3a, iC3b, FHR1, FHR2, FHR3, FHR4, and/or FHR5;
- and/or a decrease in the level of one or more of iC3b, C3f, C3c, C3dg, C3d, C3g, FI, FH, FHL-1, FHR1, FHR2, FHR3, FHR4, and/or FHR5, as compared to reference value(s) obtained previously from the same subject or obtained from a subject without a complement related disorder;
- and
- based on the results of (b), administering a therapeutically effective amount of a complement-targeted therapeutic.
25-26. (canceled)
Dependencies are inferred from the claim text.